You are here: Industry Insights > Janssen

News List

Janssen Announces FDA Approval of TREMFYA for Severe Plaque Psoriasis americanpharmaceuticalreview
July 18, 2017
Janssen Biotech announced the U.S. Food and Drug Administration (FDA) has approved TREMFYA (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
U.S. FDA approves Janssen’s TREMFYA for the treatment of moderate to severe plaque psoriasis biospectrumasia
July 18, 2017
TREMFYA (guselkumab) demonstrated superior results in skin clearance compared with Humira (adalimumab) in head-to-head analyses at weeks 16, 24 and 48.
EMA approves Janssen’s Prezista continuous manufacturing line europeanpharmaceuticalreview
June 28, 2017
The EMA has approved Janssen’s continuous manufacturing (CM) with real-time release testing for the production of Prezista (darunavir)…
Janssen Biotech, Protagonist in Exclusive PTG-200 Pact contractpharma
May 31, 2017
To develop, manufacture and commercialize PTG-200 for Crohn's disease and ulcerative colitis
EC extends approval for Janssen’s daratumumab to include multiple myeloma patients europeanpharmaceuticalreview
May 04, 2017
The European Commission (EC) has granted approval to Janssen‘s Daralex (daratumumab) for use in combination with lenalidomide and dexamethasone
Janssen scores EU approval for blood cancer drug Darzalex pharmafile
May 03, 2017
Janssen has announced that its CD38-directed monoclonal antibody Darzalex (daratumumab) has expanded its indication ...
Janssen acquires over 90% of Actelion pharmafile
April 25, 2017
Actelion has revealed that, following the wrap of its $30 billion deal in January, Janssen Holding has acquired ...
Janssen Receives Health Canada Approval of Darzalex by Priority Review for Patients with Multiple My americanpharmaceuticalreview
April 18, 2017
Janssen Inc. has announced Health Canada has approved Darzalex (daratumumab), in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior the
FDA Accepts for Review the Application of IMBRUVICA® for Chronic Graft-Versus-Host-Disease (cGVHD) americanpharmaceuticalreview
April 06, 2017
Janssen Research & Development, LLC announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for ibrutinib (IMBRUVICA®) ...
Phase 3 data for Janssen psoriasis drug shows efficacy over Humira pharmafile
March 07, 2017
Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page